Global Markets Directs, 'Streptococcus Pneumoniae (Pneumococcus)
Infections Pipeline Review, H2 2012', provides an overview of the
indications therapeutic pipeline. This report provides information on
the therapeutic development for Streptococcus Pneumoniae (Pneumococcus)
Infections, complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Streptococcus Pneumoniae
(Pneumococcus) Infections. Streptococcus Pneumoniae (Pneumococcus)
Infections Pipeline Review, Half Year is built using data and
information sourced from Global Markets Directs proprietary databases,
Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets
Directs team.
To Read The Complete Report with TOC Kindly Visit: http://www.marketresearchreports.biz/analysis/156160
Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated
disease.
For All Latest Reports Kindly Visit: http://www.marketresearchreports.biz/latest
Scope
- A snapshot of the global therapeutic scenario for Streptococcus Pneumoniae (Pneumococcus) Infections.
- A review of the Streptococcus Pneumoniae (Pneumococcus) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Streptococcus Pneumoniae (Pneumococcus) Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae (Pneumococcus) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae (Pneumococcus) Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
I suspect that anacardic acids would kill Streptococcus bacteria.
ReplyDeleteI have found that the anacardic acids in raw cashew nuts and maybe mangoes do an excellent job of curing an abscess from gram positive bacteria, which are the most prevalent cause of tooth decay and tooth aches You may see my article on this subject at; http://charles_w.tripod.com/tooth.html . It is also discussed briefly in the 2005 edition of Medical Hypotheses, 65; 289-292. Wikipedia discusses anacardic acids in http://en.wikipedia.org/wiki/Anacardic_acid .
I would like to urge you to explore making these medicines available in the pure form from pharmacies for a Streptococcus medicine or in tooth paste. This would have several advantages; 1. a variety of application methods would be possible, needles, brushes, swabs, sprays, and etc. 2. It would probably eliminate allergy. 3. It would probably be less expensive than cashews. 4. It would be easier to apply massively locally. 4. It would be easier to test against the pathogenic species involved. 5. It would be more emotionally acceptable to the medical profession who tend to prefer chemicals over anything as amateurish as natural products. 6 It would be easier to control amounts. 7. It would be easier to carry it on camping trips, etc. 7. It would probably have an infinite shelf life.
Anacardics would be much more effective in killing decay bacteria than fluoride and without the dangerous side effects (see http://charles_w,tripod.com/fluoride.html ). This would be especially valuable since these medicines would probably prove to be valuable against other gram positive diseases such as acne, leprosy, Streptococci, Staphylococcus aureus, anthrax, Listeria monocytogenes, Actinomyces naeslundi, Corynebacterium diphtheriae, Streptococcus agalactiae, Propionibacterium spp, and maybe even tuberculosis as well.
Sincerely, Charles Weber